Chemosensitization of human leukemia K562 cells to taxol by a Vanadium-salen complex

Experimental and Molecular Pathology

Volumn 89, Issue 3, 2010, Pages 334-342

  Meshkini, Azadeh ^a   Yazdanparast, Razieh ^a  

^a UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Apoptosis; Chemosensitizer; K562 cell; Taxol; Vanadium salen complex

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG; VANADIUM SALEN COMPLEX;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN K 562; CELL STRUCTURE; CHEMOSENSITIZATION; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL SEPARATION; ETHYLENEDIAMINES; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; K562 CELLS; LEUKEMIA; PACLITAXEL; VANADIUM COMPOUNDS;

EID: 78249255502     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2010.08.008     Document Type: Article

References (46)

1. Aubrecht J., Narla R.K., Ghosh P., Stanek J., Uckun F.M. Molecular genotoxicity profiles of apoptosis-inducing vanadocene complexes. Toxicol. Appl. Pharmacol. 1999, 154:228-235.
2. Basak R., Saha B.K., Chatterjee M. Inhibition of diethylnitrosamine- induced rat liver chromosomal aberrations and DNA-strand breaks by synergisitc supplementation of vanadium and 1alpha-25-dihydroxyvitamin D(3). Biochim. Biophys. Acta 2000, 1502:272-282.
3. Bhalla K., Huang Y., Tang C., Self S., Ray S., Mahoney M.E., Ponnathpur V., Tourkina E., Ibrado A.M., Bullock G. Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia 1994, 8:465-475.
4. Bianchi N., Ongaro F., Chiarabelli C., Gualandi L., Mischiati C., Bergamini P., Gambari R. Induction of erythroid differentiation of human K562 cells by cisplatin analogs. Biochem. Pharmacol. 2000, 60:31-40.
5. Boden G., Chen X., Ruiz J., van Rossum G.D.V., Turco S. Effects of vandyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 1996, 45:1130-1135.
6. Bonadies J.A., Carrano C.J. Vanadium phenolates as models for vanadium in biological system. 1. Synthesis, spectroscopy, and electrochemistry of vanadium complexes of ethylenebis [(o-hydroxyphenyl) glycin] and its derivatives. J. Am. Chem. Soc. 1986, 108:4088-4095.
7. Brown J.M., Wouters B.G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 1999, 59:1391-1399.
8. Chan S.Y., Hilchie A.L., Brown M.G., Anderson R., Hoskin D.W. Apoptosis induced by intracellular ceramide accumulation in MDA-MB-435 breast carcinoma cells is dependent on the generation of reactive oxygen species. Exp. Mol. Pathol. 2007, 82:1-11.
9. Cheng E.H.Y., Kirsch D.G., Clem R.J., Ravi R., Kastan M.B., Bedi A., Ueno K., Hardwich J.M. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 1997, 278:1966-1968.
10. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
11. Cohen N., Halberstasm M., Slimovitch P., Shammon H., Rosetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest. 1995, 95:2501-2509.
12. Copland M., Jorgensen H.G., Holyoake T.L. Evolving molecular therapy for chronic myeloid leukaemia-are we on target?. Hematology 2005, 10:349-359.
13. DCruz O.J., Uckun F.M. Metvan: a novel oxovanadium (IV) complex with broad spectrum anticancer activity. Expert Opin. Investig. Drugs 2002, 11:1829-1836.
14. Evangelou A.M. Vanadium in cancer treatment. Crit. Rev. Oncol. Hematol. 2002, 42:249-265.
15. Fawcett J.P., Farquhar S.J., Thou T., Shand B.I. Oral vanadyl sulfate does not affect blood cells, viscosity or biochemistry in humans. Pharmacol. Toxicol. 1997, 80:202-206.
16. Gambacorti-Passerini C.B., Gunby R.H., Piazza R., Galietta A., Rostagno R., Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 2003, 4:75-85.
17. Gazitt Y., Rothenberg M.L., Hilsenbeck S.G., Fey V., Thomas C., Montegomrey W. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int. J. Oncol. 1998, 13:839-848.
18. Gupta S. Molecular signaling in death receptor and mitochondrial pathways of apoptosis (Review). Int. J. Oncol. 2003, 22:15-20.
19. Haldar S., Jena N., Croce C.M. Inactivation of Bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:4507-4512.
20. Haldar S., Chintapalli J., Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate. Cancer Res. 1996, 56:1253-1255.
21. Huang Y., Ibrado A.M., Reed J.C., Bullock G., Ray S., Tang C., Bhalla K. Expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 1997, 11:253-257.
22. Itkes A.V., Imamova L.R., Alexandrova N.M., Favorova O.O., Kisselev L.L. Expression of c-myc gene in human ovary carcinoma cells treated with vanadate. Exp. Cell Res. 1990, 188:169-171.
23. Jordan M.A., Toso R.J., Thrower D., Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:9552-9556.
24. Kanik-Ennulat C., Neffm N. Vanadate-resistant mutants of Saccharomyces cerevisiae show alterations in protein phosphorylation and growth control. Mol. Cell. Biol. 1990, 10:898-909.
25. Lieu C.H., Chang Y.N., Lai Y.K. Dual cytotoxic mechanisms of submicromolar Taxol on human leukemia HL-60 cells. Biochem. Pharmacol. 1997, 53:1587-1596.
26. Lieu C.H., Liu C.C., Yu T.H., Chen K.D., Chang Y.N., Lai Y.K. Role of mitogen-activated protein kinase in Taxol-induced apoptosis in human leukemic U937 cells. Cell Growth Differ. 1998, 9:767-776.
27. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
28. Lozzio B.B., Lozzio C.B. Properties of the K562 cell line derived from a patient with chronic myeloid leukemia. Int. J. Cancer 1997, 19:136.
29. Manish A.S., Gary G.K. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin. Cancer Res. 2001, 7:2168-2181.
30. Meshkini A., Yazdanparast R. Involvement of ERK/MAPK pathway in megakaryocytic differentiation of K562 cells induced by 3-hydrogenkowadaphnine. Toxicol. In Vitro 2008, 22:1503-1510.
31. Morinville A., Maysinger D., Shaver A. From Vanadis to Atropos: vanadium compounds as pharmacological tools in cell death signaling. Trends Pharmacol. Sci. 1998, 19:452-460.
32. Ott I., Gust R. Non platinum metal complexes as anti-cancer drug. Arch. Pharm. (Weinheim) 2007, 340:117-126.
33. Pegram M.D., Lipton A., Hayes D.F., Weber B.L., Baselga J.M., Tripathy D., Baughman S.A., Twaddel T., Glaspy J.A., Slamon D.J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 (HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 1998, 16:2659-2671.
34. Pendergast A.M., Quilliam L.A., Cripe L.D., Bassing C.H., Dai Z., Li N., Batzer A., Rabun K.M., Der C.J., Schlessinger J. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993, 75:175-185.
35. Roberts J.R., Allison D.C., Donehower R.C., Rowinsky E.K. Development of polyploidization in taxol-resistance human leukemia cells in vitro. Cancer Res. 1990, 50:710-716.
36. Rowinsky E.K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med. 1997, 48:353-374.
37. Rowinsky E.K., Donehower R.C., Jones R.J., Tucker R.W. Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res. 1988, 48:4093-4100.
38. Schiff P.B., Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. U. S. A. 1980, 77:1561-1565.
39. Shepard R.L., Winter M.A., Hsaio S.C., Pearce H.L., Beck W.T., Dantzing A.H. Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein. Biochem. Pharmacol. 1998, 56:719-727.
40. Skorski T., Bellacosa A., Nieborowska-Skorska M., Majewski M., Martinez R., Choi J.K., Trotta R., Wlodarski P., Perrotti D., Chan T.O., Wasik M.A., Tsichlis P.N., Calabretta B. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 1997, 16:6151-6161.
41. 2.5 and oxidative stress in human volunteers. Cancer Epidemiol Biomark. Prev. 2005, 14:1340-1343.
42. Spencer C.M., Faulds D. Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994, 48:794-847.
43. Tang C., Willingham M.C., Reed J.C., Miyashita T., Ray S., Ponnathpur V., Huang Y., Mahoney M.E., Bullock G., Bhalla K. High levels of p26BCL-2 oncoprotein retard Taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 1994, 8:1960-1969.
44. Tsiani E., Fantus I.G. Vanadium compounds. Biological actions and potential as pharmacological agents. Trends Endocrinol. Metab. 1997, 8:51-58.
45. Wang T.H., Wang H.S., Soong Y.K. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000, 88:2619-2628.
46. Yusuf R.Z., Duan Z., Lamendola D.E., Penson R.T., Seiden M.V. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr. Cancer Drug Targets 2003, 3:1-19.